Topic Hub
6 clinically reviewed articles, written and peer-reviewed by the HealthRX Medical Team.
Explore
Showing 6 of 6 clinical reviews.
A clinical review of Vyleesi (bremelanotide) safety signals reported to the FDA Adverse Event Reporting System (FAERS), including nausea, blood pressure changes, hyperpigmentation, and injection site reactions.
Read clinical reviewComplete FDA approval timeline for Vyleesi (bremelanotide), including clinical trial data from RECONNECT, labeling details, boxed warnings, post-market safety signals, and prescribing considerations for HSDD in premenopausal women.
Read clinical reviewA complete timeline of Vyleesi (bremelanotide) FDA label updates from 2020 through 2026, covering safety revisions, boxed warning changes, post-market study requirements, and prescribing information modifications.
Read clinical reviewA clinical review of Vyleesi's regulatory history, patent disputes, FDA labeling restrictions, and post-market safety signals, with cited trial data and guideline references.
Read clinical reviewComplete regulatory profile of Vyleesi (bremelanotide): FDA approval history, label details, post-market safety data, and the melanocortin receptor pipeline beyond HSDD.
Read clinical reviewA clinical comparison of how the FDA and EMA evaluated Vyleesi (bremelanotide) for hypoactive sexual desire disorder, including approval timelines, label restrictions, safety signals, and post-market requirements.
Read clinical review